Introduction
============

Diabetes mellitus (DM) is a serious illness associated with an increased risk of cardiovascular complications, including dyslipidemia, coronary artery disease, hypertension and myocardial infarction ([@b1-ijmm-43-02-0709],[@b2-ijmm-43-02-0709]). In addition to cardiovascular injury, two other affected vital organs are the kidney \[diabetic nephropathy (DN)\] and eyes ([@b3-ijmm-43-02-0709]), with DN being one of the most common complications for patients with diabetic ([@b4-ijmm-43-02-0709],[@b5-ijmm-43-02-0709]). The pathogenesis of DN involves mesangial expansion, basement membrane thickening, glomerular hypertrophy and renal fibrosis ([@b6-ijmm-43-02-0709]-[@b8-ijmm-43-02-0709]), among which progressive renal fibrosis is the important pathological characteristic of DN ([@b9-ijmm-43-02-0709]). The epithelial-mesenchymal transition (EMT) of renal tubular epithelial cells is one of the underlying mechanisms of renal fibrosis and encompasses a range of events whereby epithelial cells no longer exhibit certain epithelial traits, such as E-cadherin expression, and instead acquire typical characteristics of mesenchymal cells, such as α-smooth muscle actin (α-SMA) expression ([@b10-ijmm-43-02-0709]). A number of studies have reported that the process is connected to the production of interstitial myofibro-blasts during nephropathy ([@b11-ijmm-43-02-0709]-[@b13-ijmm-43-02-0709]). Constant downregulation of E-cadherin is reported to occur via transcriptional repression, mediated by transcription factors including snail, slug, twist and zinc finger E-box-binding homeobox 1 (ZEB-1) ([@b14-ijmm-43-02-0709]-[@b16-ijmm-43-02-0709]), which control E-cadherin transcription by cross interaction with the E-box binding sites in the E-cadherin promoter ([@b17-ijmm-43-02-0709],[@b18-ijmm-43-02-0709]). However, the cellular molecular mechanisms underlying EMT are not completely understood ([@b19-ijmm-43-02-0709]). Therefore, it is vital to clarify the pathogenic mechanisms of EMT to formulate appropriate interventions.

Mammalian target of rapamycin (mTOR) is a serine/threonine protein kinase that regulates a series of growth-associated cellular processes. mTOR includes two complexes termed mTOR complex 1 (mTORC1) and complex 2 (mTORC2) ([@b20-ijmm-43-02-0709]). However, only mTORC1 is sensitive to rapamycin inhibition, and controls cell proliferation and growth via the phosphorylation of certain downstream targets, such as ribosomal protein S6 kinase β-1 (p70S6K) ([@b20-ijmm-43-02-0709]). Aberrant activation of the mTORC1/p70S6K pathway has been reported to be involved in the pathogenesis of DN ([@b21-ijmm-43-02-0709]). Furthermore, mTORC1/p70S6K signaling may mediate renal tubular EMT during DN ([@b19-ijmm-43-02-0709]).

Astragaloside IV (AST) is a small molecular saponin that is one of the main active ingredients extracted from Astragalus membranaceus ([@b22-ijmm-43-02-0709],[@b23-ijmm-43-02-0709]). Growing evidence has confirmed that AST has a wide spectrum of pharmacological effects ([@b24-ijmm-43-02-0709]-[@b28-ijmm-43-02-0709]). However, to the best of our knowledge, the effect of AST on the EMT of renal tubular cells during DN has not yet been reported. Therefore, the present study was performed to investigate whether AST has an effect on EMT in renal tubular cells and to clarify the potential mechanisms involved.

Materials and methods
=====================

Cell culture and intervention
-----------------------------

HK-2, the human proximal tubular epithelial cell line, was obtained from the American Type Culture Collection (Manassas, VA, USA) and cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 5.56 mmol/l D-glucose \[normal glucose (NG)\]. For induction of EMT, the HK-2 cells (at \~60% confluence) were cultivated with high glucose (HG) medium including 60 mmol/l D-glucose for 72 h ([@b19-ijmm-43-02-0709]). Mannitol medium including 5.56 mmol/l glucose and 54.44 mmol/l mannitol, was used as an osmotic control (MA). AST, purchased from Shanghai YuanYe Biotechnology Co., Ltd. (Shanghai, China), was added when the cell culture medium was changed from NG to HG medium at a concentration of 50 *µ*g/ml \[AST low (ASTL)\], 100 *µ*g/ml \[AST medium (ASTM)\] or 200 *µ*g/ml \[AST high (ASTH)\]. For the rapamycin administration group (Rap), rapamycin (Cell Signaling Technology, Inc., Danvers, MA, USA) was added at a concentration of 20 nmol/l ([@b19-ijmm-43-02-0709]).

Western blot analysis
---------------------

Protein was isolated from HK-2 cells using lysis buffer including 1% NP-40, 1 mmol/l Na~3~VO~4~, 1 mmol/l phenylmethylsulfonyl fluoride, 1 mmol/l EDTA, 20 mmol/l NaF, 50 mmol/l Tris (pH 7.6), and 150 mmol/l NaCl. The concentration of proteins was measured with a bicinchoninic acid protein assay kit (Beyotime Institute of Biotechnology, Haimen, China) following the manufacturer's protocol. For immunoblotting, equivalent quantities of protein (80 *µ*g) from the different groups were separated by SDS-PAGE on 8% gels and transferred onto polyvinylidene difluoride membranes (EMD Millipore, Billerica, MA, USA), which were blocked in TBS-Tween containing 3% bovine serum albumin (BSA) at room temperature for 1 h, and then incubated with primary antibodies at 4°C overnight. The primary antibodies against mTOR (cat. no. 2983T; 1:1,000), phospho-mTOR (Ser2448; cat. no. 5536T; 1:1,000), p70S6K (cat. no. 2708T; 1:1,000), phospho-p70S6K (Thr389; cat. no. 9234T; 1:1,000), snail (cat. no. 3879T; 1:1,000), slug (cat. no. 9585T; 1:1,000), twist (cat. no. 46702S; 1:1,000), ZEB-1 (cat. no. A1500; 1:1,000) and E-cadherin (cat. no. 3195T; 1:1,000) were purchased from Cell Signaling Technology, Inc., and against α-SMA (cat. no. ab32575; 1:1,000) and GAPDH (cat. no. ab181602; 1:1,000) from Abcam (Cambridge, UK). Secondary antibody (cat. no. C40721-02; 1:1,000) was obtained from LI-COR Biosciences, (Lincoln, NE, USA) and incubation was at 4°C overnight. Quantification was performed by measuring the signal intensity of the protein bands with ImageJ software v1.46 (National Institutes of Health, Bethesda, MD, USA).

Immunofluorescence
------------------

HK-2 cells (3×10^4^/ml) were seeded into 12-well plates containing glass coverslips. Following treatment, they were washed three times with cold PBS and then fixed with 100% cold methanol for 20 min at -20°C. Following three more washes with PBS, the HK-2 cells were blocked in 5% BSA at room temperature for 1 h, and then labeled with E-cadherin (1:200; cat. no. 3195T; Cell Signaling Technology, Inc.) and α-SMA (1:500; cat. no. ab32575; Abcam) antibodies at room temperature for 2 h. The slips were then incubated with DyLight 594 donkey anti-rabbit IgG (1:200; cat. no. E032421-01; EarthOx Life Sciences, Millbrae, CA, USA) for 1 h at room temperature. Subsequently, the nuclei were counter-stained with DAPI for 2 min, and then the cells were washed with PBS three times prior to mounting with fluorescence mounting medium. Images were captured with an Olympus BX43F fluorescence microscope (Olympus Corporation, Tokyo, Japan).

ELISA
-----

The protein levels of fibronectin (FN) and collagen type IV (Col IV) were measured via enzyme-linked immunosorbent assays (cat. nos. 30357H and 30588H; Shanghai Boyun Biotech Co., Ltd., Shanghai, China;) according to the manufacturer's instructions.

Statistical analysis
--------------------

Data are expressed as means ± standard error. Statistical analyses were performed using one-way analysis of variance for multiple data comparisons, followed by the Neuman-Keuls test. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

Effects of AST on E-cadherin expression
---------------------------------------

As demonstrated in [Fig. 1A and B](#f1-ijmm-43-02-0709){ref-type="fig"}, the HG group exhibited significantly lower E-cadherin expression compared with the NG group (P\<0.01). Additionally, the expression level of E-cadherin in the MA group did not differ significantly to that in the NG group, indicating that there were no obvious effects generated by the osmotic pressure. Rapamycin administration increased the expression of E-cadherin compared with HG treatment (P\<0.01). Notably, the ASTM- and ASTH-treated groups also exhibited markedly higher E-cadherin expression compared with the HG group (P\<0.05 and P\<0.01, respectively). These results revealed E-cadherin expression was decreased in HK-2 cells induced by high glucose, detected by western blotting and immunofluorescence, while ASTM- and ASTH treatment could increase E-cadherin expression compared with HG ([Fig. 1C](#f1-ijmm-43-02-0709){ref-type="fig"}).

Effects of AST on α-SMA expression
----------------------------------

Expression of α-SMA was upregulated in the HG group compared with the NG group (P\<0.01; [Fig. 2A and B](#f2-ijmm-43-02-0709){ref-type="fig"}). Additionally, there was no significant difference between the NG and MA groups, indicating no obvious effects generated by the osmotic pressure. In the rapamycin group, the mTOR inhibitor downregulated α-SMA expression compared with HG treatment alone (P\<0.01), and administration of AST could also significantly decrease the expression of α-SMA compared with HG alone (P\<0.01). The results were validated by immunofluorescence ([Fig. 2C](#f2-ijmm-43-02-0709){ref-type="fig"}).

Effects of AST on mTORC1/p70S6K signaling
-----------------------------------------

As demonstrated in [Fig. 3A and B](#f3-ijmm-43-02-0709){ref-type="fig"}, the HG group exhibited markedly higher levels of phosphorylated mTOR compared with the NG group (P\<0.01). Additionally, the phosphorylation of p70S6K, a main downstream target of mTOR, was also significantly increased in the HG group compared with in the NG group (P\<0.01; [Fig. 3C and D](#f3-ijmm-43-02-0709){ref-type="fig"}). These results revealed that HG activated mTORC1/p70S6K signaling. Furthermore, rapamycin reversed the abnormal activation induced by HG (P\<0.01). There was no significant difference between the NG and MA groups, indicating no obvious effects generated by the osmotic pressure alone. Notably, the AST downregulated the phosphorylation of mTOR and its main downstream target, p70S6K, indicating that AST inhibits mTORC1/p70S6K signaling.

Effects of AST on transcription factors (snail, slug, twist and ZEB-1)
----------------------------------------------------------------------

E-cadherin is a marker protein of epithelial layers and its expression is downregulated when EMT occurs ([@b14-ijmm-43-02-0709]-[@b16-ijmm-43-02-0709],[@b19-ijmm-43-02-0709]). The zinc finger transcription factors (snail, slug, twist and ZEB-1) suppress E-cadherin expression ([@b14-ijmm-43-02-0709]-[@b16-ijmm-43-02-0709],[@b19-ijmm-43-02-0709]). To verify whether these transcription factors have a role in EMT of HK-2 cells induced by high glucose, the protein expression of snail, slug, twist and ZEB-1 was determined. The expression of snail and twist was significantly enhanced in the HG group compared with in the NG group (P\<0.01), while slug and ZEB-1 expression exhibited no significant changes ([Fig. 4](#f4-ijmm-43-02-0709){ref-type="fig"}). Meanwhile, rapamycin treatment could decrease the expression of snail and twist when compared with HG treatment (P\<0.01). Interestingly, the AST administrations could also down-regulate the protein levels of snail and twist (P\<0.05, P\<0.01). In addition, there was no significant difference between the NG and MA groups, indicating no obvious effects generated by the osmotic pressure alone.

Effects of AST on FN and Col IV
-------------------------------

The major extracellular matrix (ECM) proteins FN and Col IV are regarded as markers of fibrogenesis and can cause renal fibrosis when accumulated in DN. As evident in [Fig. 5](#f5-ijmm-43-02-0709){ref-type="fig"}, the protein levels of FN and Col IV were significantly increased in the HG group compared with in the NG group (P\<0.01); and no significant differences were observed between the MA and NG groups, indicating no marked effects generated by the osmotic pressure alone. In turn, treatment with rapamycin or AST downregulated the elevated FN and Col IV levels compared with HG treatment (P\<0.01).

Discussion
==========

The incidence of DM has been increasing worldwide and as a secondary complication, DN is one of the most significant causes of end-stage renal disease ([@b29-ijmm-43-02-0709],[@b30-ijmm-43-02-0709]). In China ([@b31-ijmm-43-02-0709]) and the United States ([@b32-ijmm-43-02-0709]), \~16 and 26% of patients with DN develop end-stage renal disease, respectively; thus, effective and safe treatment strategies to delay the progression of DN are urgently required in the clinic ([@b21-ijmm-43-02-0709]). However, little progress has been made in the treatment of patients with DN ([@b33-ijmm-43-02-0709]). Although certain novel drugs, including dipeptidyl peptidase 4 inhibitors ([@b34-ijmm-43-02-0709]-[@b36-ijmm-43-02-0709]), sodium glucose cotransporter 2 inhibitors ([@b37-ijmm-43-02-0709],[@b38-ijmm-43-02-0709]) and glucagon-like peptide 1 agonists ([@b39-ijmm-43-02-0709]), can help patients presenting with early-stage DN by tightly controlling blood glucose level, it remains largely unknown whether these drugs can ameliorate EMT of renal tubular cells, which also occurs in DN.

Astragalus membranaceus, a traditional Chinese herbal medicine, is widely used as a remedy in the treatment of a variety of clinical diseases, including seasonal allergic rhinitis ([@b40-ijmm-43-02-0709]), ischemic heart disease ([@b41-ijmm-43-02-0709]), leucopenia ([@b42-ijmm-43-02-0709]) and DN ([@b43-ijmm-43-02-0709]). AST is one of the main active ingredients of Astragalus membranaceus, the potential pharmaceutical properties of which may include anti-inflammatory ([@b25-ijmm-43-02-0709]), anti-oxidative injury ([@b44-ijmm-43-02-0709]), anti-cancer ([@b28-ijmm-43-02-0709]), anti-hepatitis ([@b27-ijmm-43-02-0709]), anti-chronic heart failure ([@b26-ijmm-43-02-0709]) and anti-diabetes effects ([@b24-ijmm-43-02-0709],[@b45-ijmm-43-02-0709]). The current study aimed to determine whether AST altered EMT in renal tubular cells and to verify the potential mechanisms involved. To the best of our knowledge, the current study is the first to explore the effect and mechanism of AST on the EMT of renal tubular epithelial cells and whether the mTORC1/p70S6K signaling pathway in involved in this effect.

EMT is a physiological process required for wound healing, tissue remodeling and embryogenesis ([@b19-ijmm-43-02-0709]); however, EMT is also implicated in pathological processes of various diseases ([@b13-ijmm-43-02-0709],[@b46-ijmm-43-02-0709]). For example, during DN, renal tubular epithelial cells undergo a trans-differentiation process and become myofibroblasts, which are the primary source of ECM in renal cells. Major ECM proteins, including FN and Col IV, are often regarded as markers of fibrogenesis ([@b47-ijmm-43-02-0709]-[@b49-ijmm-43-02-0709]), and their accumulation in patients with DN can lead to renal fibrosis ([@b11-ijmm-43-02-0709],[@b50-ijmm-43-02-0709]).

In the present study, the detection of EMT marker proteins demonstrated that high glucose significantly downregulated E-cadherin expression and upregulated the generation of α-SMA. Furthermore, levels of FN and Col IV were increased by high glucose. In turn, treatment with AST could ameliorate the changes stimulated by high glucose. Previous studies have indicated that the mTORC1/p70S6K pathway has an important role in DN, with blockade of this pathway reported to slow DN development ([@b19-ijmm-43-02-0709],[@b21-ijmm-43-02-0709]).

It was previously reported that quercetin effectively ameliorated the high glucose-induced EMT of HK-2 and NRK-52E cells and inhibited the activation of mTORC1/p70S6K ([@b19-ijmm-43-02-0709]). *In vivo*, diabetic rats exhibited a significant decline in renal function and severe renal fibrosis at 14 weeks after STZ injection, and mTORC1/p70S6K was activated in the renal cortex of the diabetic rats. Treatment with quercetin alleviated the decline in renal function, and the progression of renal fibrosis and inhibited mTORC1/p70S6K activation in the diabetic renal cortex ([@b19-ijmm-43-02-0709]). A HK-2 cell model was validated in the previous study, and based on this, HK-2 cells treated with high glucose was selected as the cell model to verify the effects of AST on EMT in the present study. The results of the current study confirmed previous findings, revealing that the phosphorylation of mTOR and its downstream target, p70S6K, was markedly increased in HK-2 cells induced by high glucose. Treatment with rapamycin inhibited the activation of the mTORC1/p70S6K pathway. Additionally, the association of mTORC1/p70S6K signaling with the EMT of renal tubular epithelial cells was confirmed. Notably, a study by Lu *et al* ([@b19-ijmm-43-02-0709]) indicated that the mTORC1/p70S6K pathway is also involved in the regulation of transcription factor expression, including snail and twist. In the present study, inhibiting mTORC1/p70S6K signaling via rapamycin downregulated the increased protein expression of snail and twist induced by high glucose. These results indicated that activation of mTORC1/p70S6K signaling promoted the progression of EMT by regulating snail and twist expression. Furthermore, AST administration inhibited the mTORC1/p70S6K pathway and reduced the expression of snail and twist; the potential mechanism is illustrated in [Fig. 6](#f6-ijmm-43-02-0709){ref-type="fig"}. However, not studying more markers was a limitation of the present study. The findings of the present study require further validation in the future.

In conclusion, to the best of our knowledge, the present study is the first research to determine the effects of AST on EMT in HK-2 cells via the mTORC1/p70S6K signaling pathway. The present findings provided confirmation that AST reduces EMT in renal tubular cells stimulated by high glucose via mTORC1/p70S6K signaling, and subsequent downregulation of the expression of the transcription factors snail and twist in HK-2 cells. The conclusions will be validated using in vivo models in future studies.
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![Effects of AST on E-cadherin expression in HK-2 cells. (A) Western blot analysis of E-cadherin. (B) Densitometry analysis of E-cadherin. (C) Expression of E-cadherin via immunofluorescence. Data are expressed as the mean ± standard error. n=3. Scale bar, 20 *µ*m. ^\*\*^P\<0.01 vs. NG; ^\#^P\<0.05 vs. HG group; ^\#\#^P\<0.01 vs. HG group. AST, astragaloside IV; NG, normal glucose 5.56 mmol/l; MA, normal glucose 5.56 mmol/l + mannitol 54.44 mmol/l; HG, high glucose 60 mmol/l; Rap, high glucose + 20 nmol/l rapamycin; ASTL, high glucose + 50 *µ*g/ml AST; ASTM, high glucose + 100 *µ*g/ml AST; ASTH, high glucose + 200 *µ*g/ml AST.](IJMM-43-02-0709-g00){#f1-ijmm-43-02-0709}

![Effects of AST on α-SMA expression in HK-2 cells. (A) Western blotting bands of α-SMA. (B) Densitometry analysis of α-SMA. (C) Expression of α-SMA via immunofluorescence. Data are expressed as the mean ± standard error. n=3. Scale bar, 20 *µ*m.^\*\*^P\<0.01 vs. NG; ^\#\#^P\<0.01 vs. HG group. AST, astragaloside IV; NG, normal glucose 5.56 mmol/l; MA, normal glucose 5.56 mmol/l + mannitol 54.44 mmol/l; HG, high glucose 60 mmol/l; Rap, high glucose + 20 nmol/l rapamycin; ASTL, high glucose + 50 *µ*g/ml AST; ASTM, high glucose + 100 *µ*g/ml AST; ASTH, high glucose + 200 *µ*g/ml AST; α-SMA, α-smooth muscle actin.](IJMM-43-02-0709-g01){#f2-ijmm-43-02-0709}

![Effects of AST on mTORC1/p70S6K signaling in HK-2 cells. (A) Western blot analysis of p-mTOR. (B) Densitometry analysis of p-mTOR. (C) Western blot analysis of p-p70S6K. (D) Densitometry analysis of p-p70S6K. Data are expressed as mean ± standard error. n=3. ^\*\*^P\<0.01 vs. NG group; ^\#^P\<0.05 vs. HG group; ^\#\#^P\<0.01 vs. HG group. AST, astragaloside IV; NG, normal glucose 5.56 mmol/l; MA, normal glucose 5.56 mmol/l + mannitol 54.44 mmol/l; HG, high glucose 60 mmol/l; Rap, high glucose + 20 nmol/l rapamycin; ASTL, high glucose + 50 *µ*g/ml AST; ASTM, high glucose + 100 *µ*g/ml AST; ASTH, high glucose + 200 *µ*g/ml AST; p- phospho-; mTOR, mammalian target of rapamycin; p70S6K, ribosomal protein S6 kinase β-1.](IJMM-43-02-0709-g02){#f3-ijmm-43-02-0709}

![Effects of AST on transcriptional factors, snail, slug, twist and ZEB-1. (A) Western blot analysis of snail, slug, twist and ZEB-1. Relative abundance of (B) snail, (C) slug, (D) twist and (E) ZEB-1. Data are expressed as mean ± standard error. n=3. ^\*\*^P\<0.01 vs. NG group; ^\#^P\<0.05 vs. HG group; ^\#\#^P\<0.01 vs. HG group. AST, astragaloside IV; NG, normal glucose 5.56 mmol/l; MA, normal glucose 5.56 mmol/l + mannitol 54.44 mmol/l; HG, high glucose 60 mmol/l; Rap, high glucose + 20 nmol/l rapamycin; ASTL, high glucose + 50 *µ*g/ml AST; ASTM, high glucose + 100 *µ*g/ml AST; ASTH, high glucose + 200 *µ*g/ml AST; ZEB-1, zinc finger E-box-binding homeobox 1.](IJMM-43-02-0709-g03){#f4-ijmm-43-02-0709}

![Effects of AST on FN and IV Col. (A) Relative abundance of FN. (B) Relative abundance of IV Col. Data are expressed as the mean ± standard error. n=3. ^\*\*^P\<0.01 vs. NG group; ^\#\#^P\<0.01 vs. HG group. FN, fibronectin; AST, astragaloside IV; NG, normal glucose 5.56 mmol/l; MA, normal glucose 5.56 mmol/l + mannitol 54.44 mmol/l; HG, high glucose 60 mmol/l; Rap, high glucose + 20 nmol/l rapamycin; ASTL, high glucose + 50 *µ*g/ml AST; ASTM, high glucose + 100 *µ*g/ml AST; ASTH, high glucose + 200 *µ*g/ml AST; IV Col, collagen type IV.](IJMM-43-02-0709-g04){#f5-ijmm-43-02-0709}

![Mechanism of AST ameliorates high glucose-mediated renal tubular epithelial-mesenchymal transition. AST, astragaloside IV; mTOR, mammalian target of rapamycin; p70S6K, ribosomal protein S6 kinase β-1; P, phospho-; α-SMA, α-smooth muscle actin; FN, fibronectin; IV Col, collagen type IV.](IJMM-43-02-0709-g05){#f6-ijmm-43-02-0709}
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